<DOC>
	<DOCNO>NCT02651727</DOCNO>
	<brief_summary>The purpose study evaluate increase dose level VS-4718 administer combination gemcitabine nab-paclitaxel subject advance cancer determine recommend Phase 2 dose ( RP2D ) development combination subject untreated advanced pancreatic cancer .</brief_summary>
	<brief_title>Ph 1 Study VS-4718 , FAK Inhibitor , Combination With Nab-paclitaxel Gemcitabine Advanced Cancer Subjects</brief_title>
	<detailed_description>The study comprise 2 sequential part : Part A ( Dose Escalation VS-4718 ) subject advanced cancer Part B ( Expansion ) subject untreated advanced pancreatic cancer . Up 60 evaluable subject ( i.e. , subject complete least 1 cycle ( 28 day ) therapy ) enrol , assume : 1 . Part A : The maximum sample size 6 subject 4 dose level ( exclusive replacement subject ) . However , additional subject may add exploration intermediate dose level ( ) VS 4718 warrant . The start dose VS-4718 200mg BID . 2 . Part B : Up 36 additional subject may enrol RP2D . These subject randomize 1:1 ratio 1 2 treatment cohort : - Cohort 1 : IV treatment 28-day cycle ( nab-paclitaxel 125 mg/m2 30 minute Days 1 , 8 , 15 gemcitabine 1000 mg/m2 30 minute Days 1 , 8 , 15 ) oral VS 4718 BID continuously start Day 1 Cycle 1 - Cohort 2 : IV treatment first 2 cycle , follow IV treatment oral VS-4718 BID continuously start Day 1 Cycle 3</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age ≥ 18 year Histologically cytologically confirm diagnosis advance nonhematological malignancy ( Part A ) advance pancreatic adenocarcinoma ( Part B ) surgically resectable Eligible treatment nabpaclitaxel gemcitabine Days 1 , 8 , 15 28day cycle standard therapy Evaluable measurable disease , assessed RECIST v1.1 ECOG performance status ≤ 1 Adequate renal function ( creatinine ≤ 1.5×ULN [ upper limit normal ] ) glomerular filtration rate ≥ 60 mL/min Adequate hepatic function ( total bilirubin ≤ 1.5×ULN institution ; aspartate transaminase alanine transaminase ≤ 2.5×ULN , ≤ 5×ULN due liver involvement tumor ; albumin ≥ 3 g/dL ) Adequate bone marrow function ( hemoglobin ≥ 9.0 g/dL ; unsupported platelet ≥ 100×109 cells/L ; absolute neutrophil count [ ANC ] ≥ 1.5×109 cells/L without use hematopoietic growth factor ) Corrected QT interval ( QTc ) &lt; 470 m Willing able participate trial comply trial requirement Gastrointestinal ( GI ) condition could interfere swallow absorption study medication Uncontrolled severe concurrent medical condition ( include uncontrolled brain metastasis ) . History upper gastrointestinal bleeding , ulceration , perforation within 6 month prior first dose protocol therapy Known history stroke cerebrovascular accident within 6 month prior first dose protocol therapy . Part B : Prior therapy ( include investigational agent ) pancreatic cancer Chemotherapy radiotherapy within 14 day prior first dose protocol therapy Active treatment secondary malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>